Skip to content
ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Note

Cross-sectional study of IgG antibody levels to invasive nontyphoidal Salmonella LPS O-antigen with age in Uganda

[version 1; peer review: 2 approved, 2 approved with reservations]
* Equal contributors
PUBLISHED 26 Jun 2019
Author details Author details

Abstract

Invasive nontyphoidal Salmonella (iNTS) disease is a major cause of deaths among children and HIV-infected individuals in sub-Saharan Africa. Acquisition of IgG to iNTS lipopolysaccharide (LPS) O-antigen in Malawi in early childhood corresponds with a fall in cases of iNTS disease suggesting that vaccines able to induce such antibodies could confer protection. To better understand the acquisition of IgG to iNTS in other African settings, we performed a cross-sectional seroepidemiological study using sera from 1090 Ugandan individuals aged from infancy to old age. Sera were analysed for IgG to LPS O-antigen of S. Typhimurium and S. Enteritidis using an in-house ELISA. Below 18 months of age, most children lacked IgG to both serovars. Thereafter, specific IgG levels increased with age, peaking in adulthood, and did not wane noticeably in old age. There was no clear difference in antibody levels between the sexes and the few HIV-infected individuals in the study did not have obviously different levels from uninfected subjects. While IgG to iNTS is acquired at a younger age in Malawian compared with Ugandan children, it is not clear whether this is due to differences in the populations themselves, their exposure to iNTS, or variations between assays used. In conclusion, there is a need to develop a harmonised method and standards for measuring antibodies to iNTS across studies and to investigate acquisition of such antibodies with age across different sites in sub-Saharan Africa.

Keywords

non-typhoidal salmonella, NTS, antibody, Uganda

Introduction

Invasive non-typhoidal Salmonella (iNTS) disease is principally caused by serovars S. Typhimurium and S. Enteritidis and is thought to be responsible for up to 680,000 deaths annually, with Africa accounting for more than half of cases1. Much of this burden is in children under 5 years and HIV-infected adults. In view of this major global burden of disease, and rapid emergence of multidrug resistant iNTS strains2, development of a vaccine is increasingly vital3.

Studies in Malawian children indicate that anti-S. Typhimurium antibodies, notably IgG to O-antigen of LPS and flagellin, and serum bactericidal activity rises rapidly with age in the first few years of life corresponding with a fall in cases of iNTS disease4,5. One study found a positive correlation between serum bactericidal assay (SBA) killing and acquisition of anti-LPS IgG5. However, there is no standardised assay for measurement of iNTS-specific IgG, and the clinical significance of the iNTS SBA is unknown. Given that incidence of iNTS disease drops in children over 2 years, it has been suggested that a rise in specific antibodies and bactericidal activity correlates with protection. This hypothesis is complicated by the observation that among HIV-infected Malawian adults, high LPS-specific IgG was associated with a lack of in vitro bacterial killing6.

Methods

In a cross-sectional study, we investigated NTS-specific antibody responses in the rural Ugandan General Population Cohort (GPC)7. Levels of IgG against serovars S. Typhimurium and S. Enteritidis LPS O-antigens were measured using a standardised in-house ELISA in stored sera from a cross-section of 1,090 Ugandans of all ages, 10 of whom were HIV-infected. Sera from adults (≥ 16 years) were collected from January 2014 to November 2015, and children (<16 years) from January 2016 to November 2017. Antibody units (AU) were calculated using Gen5 software (version 2.0) using a five-parameter logistic (5PL) curve generated with a standard serum from an iNTS-exposed individual. Sera were defined as seronegative if below the lower limit of detection (4 AU for S. Typhimurium and 5 AU for S. Enteritidis) at 1:100 serum dilution.

Written informed consent for the use of clinical records and biological samples for research purposes was obtained from all GPC participants following Uganda National Council of Science and Technology guidelines. Ethical approval for the use of samples for this study was obtained from The UVRI Research and Ethics Committee and from the Uganda Council for Science and Technology (Ref: GC/127/19/10/710).

Results and discussion

In this assay, overall O-antigen seropositivity was 82% for S. Typhimurium, and was 70% for S. Enteritidis. Levels of antibody were undetectable in at least 50% of children until 18 months for both serovars and a similar pattern of increasing IgG level was observed with increasing age (Figure 1A, B). There were no observable differences in antibody levels by sex (Figure 1C, D). HIV-infected individuals did not have notably high IgG antibody responses, although the study was not powered to demonstrate this.

1568081a-3dbc-485b-a31f-fc689d63240c_figure1.gif

Figure 1.

Plots showing antibody units (AU) for S. Typhimurium (A and C) and S. Enteritidis (B and D) by age. Orange dots indicate HIV infected individuals. (A, B). Females are indicated in red and males in blue (C, D). The box shows the interquartile range (IQR) with middle line representing the median. The whiskers represent the adjacent values, defined as 1.5 × IQR from the edge of the box, with values outside this range shown individually. LLOQ, lower limit of quantification.

Although performed using a flow cytometric assay, previously published data from Malawi suggest that NTS-specific IgG is present in the majority of children throughout infancy4, contrasting with our results from Uganda. This could be due to variation in exposure to iNTS in Uganda compared to Malawi, or differences in assays. However, burden of, and exposure to, iNTS disease in Uganda is not well understood. A standardised assay is key to understanding variation in exposure across geographic locations to support vaccine development.

Data availability

Open Science Framework: Invasive Non-Typhoidal Salmonella serology in Uganda. https://doi.org/10.17605/OSF.IO/68BYT8.

This project contains the age, sex, antibody levels, HIV status and Salmonella status of each participant.

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 26 Jun 2019
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
Gates Open Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Stockdale L, Nalwoga A, Nash S et al. Cross-sectional study of IgG antibody levels to invasive nontyphoidal Salmonella LPS O-antigen with age in Uganda [version 1; peer review: 2 approved, 2 approved with reservations]. Gates Open Res 2019, 3:1501 (https://doi.org/10.12688/gatesopenres.13034.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 26 Jun 2019
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions

Are you a Gates-funded researcher?

If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research.

You must provide your first name
You must provide your last name
You must provide a valid email address
You must provide an institution.

Thank you!

We'll keep you updated on any major new updates to Gates Open Research

Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.